API Holdings, the parent of e-pharmacy and diagnostics brand PharmEasy, reported flat revenue in the fiscal year ending March 2025. However, the Mumbai-based company has cut losses by 38% due to sharp reduction in finance and depreciation costs during the last fiscal year.
PharmEasy’s operating revenue increased 3.7% to Rs 5,872 crore in FY25 from Rs 5,664 crore in FY24, according to the company’s financial statements reviewed by Entrackr.
/filters:format(webp)/entrackr/media/media_files/2025/09/08/pharmeasy-financials-2025-09-08-16-01-16.png)
PharmEasy offers pharmaceutical products, along with diagnostic services and teleconsultations, through its…








